Logo

Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

Share this

Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

Shots:

  • The companies initiate the clinical trial of A2a receptor antagonist- co-developed by Exscientia and Evotec utilizing Exscientia's AI-design platform- Centaur Chemist
  • Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development
  • The A2a receptor is currently in development for adult patients with advanced solid tumors and has the potential to show high selectivity for the targeted receptor

  Ref: Evotec | Image: Wikipedia

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions